Trials / Completed
CompletedNCT05841238
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
A Multiple Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tablet and Capsule Formulations of LY3502970 in Healthy Overweight and Obese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3502970 | Administered orally. |
Timeline
- Start date
- 2023-04-26
- Primary completion
- 2023-09-14
- Completion
- 2023-11-13
- First posted
- 2023-05-03
- Last updated
- 2024-10-02
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05841238. Inclusion in this directory is not an endorsement.